AA
IONS icon

ALPS Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

ALPS Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-77,480
Closed -$3.43M – 1058
2022
Q3 		$3.43M Sell
77,480
-6,635
-8% -$280K 0.03% 204
2022
Q2 		$3.11M Sell
84,115
-61,500
-42% -$2.32M 0.03% 232
2022
Q1 		$5.39M Sell
145,615
-17,809
-11% -$583K 0.06% 127
2021
Q4 		$4.97M Buy
+163,424
New +$5.14M 0.06% 150
2017
Q2 		– Sell
-103,538
Closed -$4.16M – 779
2017
Q1 		$4.16M Buy
103,538
+3,988
+4% +$179K 0.03% 146
2016
Q4 		$4.76M Sell
99,550
-54,602
-35% -$2.16M 0.04% 138
2016
Q3 		$5.65M Sell
154,152
-15,524
-9% -$486K 0.05% 131
2016
Q2 		$3.95M Buy
+169,676
New +$5.47M 0.04% 136

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

ALPS Advisors's IONS Position: Q4 2022 in Review

ALPS Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2022, closing a stake of 77,480 shares — an estimated $3.43M sold.

ALPS Advisors first reported a position in IONS in Q2 2016 and held it in 8 quarters. The position peaked at $5.65M in Q3 2016. 338 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

  • ALPS Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 77,480 Ionis Pharmaceuticals shares in Q4 2022, an estimated $3.43M.
  • ALPS Advisors first reported a position in Ionis Pharmaceuticals in Q2 2016 and held it in 8 quarters.
  • ALPS Advisors's Ionis Pharmaceuticals position peaked at $5.65M in Q3 2016.
  • 338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.